- call +1-201-465-4211
- email sales@mrinsights.biz
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence.
Scope of the Report:
This report studies the Prostate Cancer Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Prostate Cancer Medicine market by product type and applications/end industries.
The global Prostate Cancer Medicine market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Prostate Cancer Medicine.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
AstraZeneca plc
Active Biotech
Bristol Myers-Squibb
Teva Pharmaceuticals Industries Ltd.
Johnson & Johnson
Pfizer Inc.
Bayer AG
Abbott Laboratories
Astellas Pharma Inc.
Roche Holding AG
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
LHRH Antagonists
LHRH Analogs
Antiandrogens
Pipeline Drugs for Hormonal Therapy
Market Segment by Applications, can be divided into
Hospitals
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Prostate Cancer Medicine Market Overview
1.1 Product Overview and Scope of Prostate Cancer Medicine
1.2 Classification of Prostate Cancer Medicine by Types
1.2.1 Global Prostate Cancer Medicine Revenue Comparison by Types (2017-2023)
1.2.2 Global Prostate Cancer Medicine Revenue Market Share by Types in 2017
1.2.3 LHRH Antagonists
1.2.4 LHRH Analogs
1.2.5 Antiandrogens
1.2.6 Pipeline Drugs for Hormonal Therapy
1.3 Global Prostate Cancer Medicine Market by Application
1.3.1 Global Prostate Cancer Medicine Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Other
1.4 Global Prostate Cancer Medicine Market by Regions
1.4.1 Global Prostate Cancer Medicine Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Prostate Cancer Medicine Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Prostate Cancer Medicine Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Prostate Cancer Medicine Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Prostate Cancer Medicine Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Prostate Cancer Medicine Status and Prospect (2013-2023)
1.5 Global Market Size of Prostate Cancer Medicine (2013-2023)
2 Manufacturers Profiles
2.1 AstraZeneca plc
2.1.1 Business Overview
2.1.2 Prostate Cancer Medicine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca plc Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.2 Active Biotech
2.2.1 Business Overview
2.2.2 Prostate Cancer Medicine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Active Biotech Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol Myers-Squibb
2.3.1 Business Overview
2.3.2 Prostate Cancer Medicine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol Myers-Squibb Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceuticals Industries Ltd.
2.4.1 Business Overview
2.4.2 Prostate Cancer Medicine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceuticals Industries Ltd. Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.5 Johnson & Johnson
2.5.1 Business Overview
2.5.2 Prostate Cancer Medicine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Johnson & Johnson Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer Inc.
2.6.1 Business Overview
2.6.2 Prostate Cancer Medicine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Inc. Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bayer AG
2.7.1 Business Overview
2.7.2 Prostate Cancer Medicine Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bayer AG Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.8 Abbott Laboratories
2.8.1 Business Overview
2.8.2 Prostate Cancer Medicine Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Abbott Laboratories Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.9 Astellas Pharma Inc.
2.9.1 Business Overview
2.9.2 Prostate Cancer Medicine Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Astellas Pharma Inc. Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
2.10 Roche Holding AG
2.10.1 Business Overview
2.10.2 Prostate Cancer Medicine Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Roche Holding AG Prostate Cancer Medicine Revenue, Gross Margin and Market Share (2016-2017)
3 Global Prostate Cancer Medicine Market Competition, by Players
3.1 Global Prostate Cancer Medicine Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Prostate Cancer Medicine Players Market Share
3.2.2 Top 10 Prostate Cancer Medicine Players Market Share
3.3 Market Competition Trend
4 Global Prostate Cancer Medicine Market Size by Regions
4.1 Global Prostate Cancer Medicine Revenue and Market Share by Regions
4.2 North America Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
4.3 Europe Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
4.5 South America Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
5 North America Prostate Cancer Medicine Revenue by Countries
5.1 North America Prostate Cancer Medicine Revenue by Countries (2013-2018)
5.2 USA Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
5.3 Canada Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
5.4 Mexico Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
6 Europe Prostate Cancer Medicine Revenue by Countries
6.1 Europe Prostate Cancer Medicine Revenue by Countries (2013-2018)
6.2 Germany Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
6.3 UK Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
6.4 France Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
6.5 Russia Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
6.6 Italy Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Prostate Cancer Medicine Revenue by Countries
7.1 Asia-Pacific Prostate Cancer Medicine Revenue by Countries (2013-2018)
7.2 China Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
7.3 Japan Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
7.4 Korea Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
7.5 India Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
8 South America Prostate Cancer Medicine Revenue by Countries
8.1 South America Prostate Cancer Medicine Revenue by Countries (2013-2018)
8.2 Brazil Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
8.3 Argentina Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
8.4 Colombia Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Prostate Cancer Medicine by Countries
9.1 Middle East and Africa Prostate Cancer Medicine Revenue by Countries (2013-2018)
9.2 Saudi Arabia Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
9.3 UAE Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
9.4 Egypt Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
9.5 Nigeria Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
9.6 South Africa Prostate Cancer Medicine Revenue and Growth Rate (2013-2018)
10 Global Prostate Cancer Medicine Market Segment by Type
10.1 Global Prostate Cancer Medicine Revenue and Market Share by Type (2013-2018)
10.2 Global Prostate Cancer Medicine Market Forecast by Type (2018-2023)
10.3 LHRH Antagonists Revenue Growth Rate (2013-2023)
10.4 LHRH Analogs Revenue Growth Rate (2013-2023)
10.5 Antiandrogens Revenue Growth Rate (2013-2023)
10.6 Pipeline Drugs for Hormonal Therapy Revenue Growth Rate (2013-2023)
11 Global Prostate Cancer Medicine Market Segment by Application
11.1 Global Prostate Cancer Medicine Revenue Market Share by Application (2013-2018)
11.2 Prostate Cancer Medicine Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Other Revenue Growth (2013-2018)
12 Global Prostate Cancer Medicine Market Size Forecast (2018-2023)
12.1 Global Prostate Cancer Medicine Market Size Forecast (2018-2023)
12.2 Global Prostate Cancer Medicine Market Forecast by Regions (2018-2023)
12.3 North America Prostate Cancer Medicine Revenue Market Forecast (2018-2023)
12.4 Europe Prostate Cancer Medicine Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Prostate Cancer Medicine Revenue Market Forecast (2018-2023)
12.6 South America Prostate Cancer Medicine Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Prostate Cancer Medicine Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Prostate Cancer Medicine Picture
Table Product Specifications of Prostate Cancer Medicine
Table Global Prostate Cancer Medicine and Revenue (Million USD) Market Spli
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
